Building the Backbone of Metabolic Health: Our Investment in Nourish

Sixty percent of American adults live with some kind of cardiometabolic condition — diabetes, obesity, heart disease — and the fix doctors keep recommending is embarrassingly low-tech: talk to a dietitian. Insurance has covered that conversation for over a decade. Almost nobody uses it. Menlo Ventures pegs utilization at under 1%, not because the benefit doesn't exist, but because the supply side was a mess of scattered small practices with opaque billing and zero marketing muscle.

Nourish, founded by Aidan, Stephanie, and Sam — all three drawing on their own frustrating experiences trying to access dietitian care — built the plumbing that was missing. Patients get matched with a registered dietitian and book a virtual, insurance-covered session in minutes, often for little or no out-of-pocket cost. Behind the scenes, Nourish handles credentialing, claims, scheduling, and clinical documentation, the unglamorous work that used to eat up a dietitian's day. The company now counts more than 10,000 registered dietitians across all 50 states and says it serves hundreds of thousands of patients.

What's pushing this from niche to necessary is the GLP-1 wave. Ozempic and its cousins created a huge population of patients who need nutritional support to make the weight loss stick, and insurers are starting to require dietitian visits as a condition of covering the drugs. Menlo compares the moment to behavioral health a few years back, when COVID-era demand turned Grow Therapy (another Menlo bet) from a good idea into a category-defining company. Nourish leans on AI to make the scaling work — automated session notes, clinical insights pulled from patient data, background prior-authorization handling — and it's also built something rarer: a pharma-style field sales team that turns physicians into steady referral sources, rather than relying on patients to find the platform themselves.

Menlo's $100M Series C slots Nourish into what the firm calls its